Avenir® Cemented Hip Stem - PMCF
← catalyst calendarNCT03396224 · readout ≤ 1,564 d
Sponsored by Zimmer Biomet (industry) · ZBH — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
100actual
Sites
3
Countries
Belgium, France
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2015-11-18 | actual | When the study began enrolling |
| Primary completion | Nov 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2018-01-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Primary Osteoarthritis
- Post-Traumatic Osteoarthritis of Hip
- Femoral Neck Fractures
- Femoral Head Necrosis
- Sequelae From Previous Hip Surgery
- Osteotomies
- Congenital Hip Dysplasia
Primary outcome
what the primary-completion date above is the date OFImplant survival based on removal or intended removal of the device and determined using the Kaplan-Meier method
measured 10 years
Permalink · ZBH's whole pipeline · Catalyst calendar · Every registered study · What changed